drugset / Trial / NCT07414979
Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The proposed study is a single arm Phase I trial aimed at treating up to 6 HLA-A\*0201+ and HLA-A\*24 02+ individuals with leptomeningeal disease from metastatic melanoma.
Timeline
- Start
- 2026-08-31
- Primary completion
- 2028-03-22
- Completion
- 2030-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD8+T cells | Cell therapy | 3e+08 cells | Other |
| Subject | CD8+T cells | Cell therapy | 1e+09 cells | Other |